TScan Therapeutics, Inc. (TCRX) 10-Year Financial Performance & Capital Metrics

TCRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutTScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Show more

Revenue $3M -86.6%
EBITDA -$131M -48.4%
Net Income -$127M -42.9%
EPS (Diluted) -1.14 +16.2%
Gross Margin 100%
EBITDA Margin -4641.8% -1009.1%
Operating Margin -4787.68% -978.3%
Net Margin -4527.66% -968.2%
ROE -65.08% +8.7%
ROIC -75.01% +6.2%
Debt/Equity 0.40 -34.0%
Interest Coverage -36.91 -48.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Shares diluted 70.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-34.76%

TTM-10.03%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-28.12%

EPS CAGR

10Y-

5Y-

3Y-

TTM-5.66%

ROCE

10Y Avg-45.72%

5Y Avg-48.81%

3Y Avg-43%

Latest-46.69%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.08M	10.14M	13.54M	21.05M	2.82M
Revenue Growth %	-	-	8.35%	0.33%	0.56%	-0.87%
Cost of Goods Sold+	9.44M	20.58M	0	0	0	0
COGS % of Revenue	-	18.96%	-	-	-	-
Gross Profit+	-9.44M	-19.49M	10.14M	13.54M	21.05M	2.82M
Gross Margin %	-	-17.96%	1%	1%	1%	1%
Gross Profit Growth %	-	-1.06%	1.52%	0.33%	0.56%	-0.87%
Operating Expenses+	4.77M	6.74M	58.78M	80.17M	114.51M	137.64M
OpEx % of Revenue	-	6.21%	5.8%	5.92%	5.44%	48.88%
Selling, General & Admin	4.77M	6.74M	13.83M	20.35M	25.49M	29.56M
SG&A % of Revenue	-	6.21%	1.36%	1.5%	1.21%	10.5%
Research & Development	9.44M	20.58M	44.95M	59.82M	88.15M	107.35M
R&D % of Revenue	-	18.96%	4.43%	4.42%	4.19%	38.12%
Other Operating Expenses	-9.44M	-20.58M	0	0	862K	728K
Operating Income+	-14.21M	-26.23M	-48.64M	-66.64M	-93.46M	-134.82M
Operating Margin %	-	-24.18%	-4.8%	-4.92%	-4.44%	-47.88%
Operating Income Growth %	-	-0.85%	-0.85%	-0.37%	-0.4%	-0.44%
EBITDA+	-13.69M	-25M	-45.31M	-61.5M	-88.1M	-130.71M
EBITDA Margin %	-	-23.04%	-4.47%	-4.54%	-4.19%	-46.42%
EBITDA Growth %	-	-0.83%	-0.81%	-0.36%	-0.43%	-0.48%
D&A (Non-Cash Add-back)	519K	1.23M	3.33M	5.14M	5.36M	4.11M
EBIT	-14.21M	-26.23M	-48.63M	-65.05M	-85.46M	-123.85M
Net Interest Income+	552K	106K	16K	415K	4.24M	8.41M
Interest Income	552K	106K	16K	1.59M	8M	12.06M
Interest Expense	0	0	0	1.18M	3.76M	3.65M
Other Income/Expense	552K	106K	16K	415K	4.24M	7.32M
Pretax Income+	-13.66M	-26.13M	-48.63M	-66.22M	-89.22M	-127.5M
Pretax Margin %	-	-24.08%	-4.79%	-4.89%	-4.24%	-45.28%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-13.66M	-26.13M	-48.63M	-66.22M	-89.22M	-127.5M
Net Margin %	-	-24.08%	-4.79%	-4.89%	-4.24%	-45.28%
Net Income Growth %	-	-0.91%	-0.86%	-0.36%	-0.35%	-0.43%
Net Income (Continuing)	-13.66M	-26.13M	-48.63M	-66.22M	-89.22M	-127.5M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.53	-1.04	-2.03	-2.74	-1.36	-1.14
EPS Growth %	-	-0.96%	-0.95%	-0.35%	0.5%	0.16%
EPS (Basic)	-0.53	-1.04	-2.03	-2.74	-1.36	-1.14
Diluted Shares Outstanding	24.94M	24.94M	23.91M	24.05M	65.6M	111.99M
Basic Shares Outstanding	24.94M	24.94M	23.91M	24.05M	65.6M	111.99M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	42.38M	36.45M	165.65M	124.13M	194.24M	292.72M
Cash & Short-Term Investments	41.76M	34.79M	161.41M	120.03M	192.04M	290.11M
Cash Only	41.76M	34.79M	161.41M	120.03M	133.36M	178.69M
Short-Term Investments	0	0	0	0	58.69M	111.42M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	4.25M	4.1M	2.19M	2.61M
Total Non-Current Assets+	7M	13.29M	22.45M	74.96M	77.91M	78.4M
Property, Plant & Equipment	6.41M	12.53M	17.26M	69.2M	71.23M	71.6M
Fixed Asset Turnover	-	0.09x	0.59x	0.20x	0.30x	0.04x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	5.2M	5.04M	0	0
Other Non-Current Assets	595K	761K	0	725K	6.68M	6.8M
Total Assets+	49.38M	49.74M	188.11M	199.09M	272.15M	371.12M
Asset Turnover	-	0.02x	0.05x	0.07x	0.08x	0.01x
Asset Growth %	-	0.01%	2.78%	0.06%	0.37%	0.36%
Total Current Liabilities+	2.4M	17.45M	21.34M	17.3M	29.82M	35.96M
Accounts Payable	1.01M	2.91M	1.76M	2.91M	2.37M	4.28M
Days Payables Outstanding	39.04	51.62	-	-	-	-
Short-Term Debt	0	0	1.65M	3.68M	3.35M	0
Deferred Revenue (Current)	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	31K	1.67M	3.92M	2.48M	5.9M	6.92M
Current Ratio	17.69x	2.09x	7.76x	7.17x	6.51x	8.14x
Quick Ratio	17.69x	2.09x	7.76x	7.17x	6.51x	8.14x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	4.44M	74.75M	5.99M	82.35M	91.46M	94.19M
Long-Term Debt	0	0	0	29.29M	26.7M	32.07M
Capital Lease Obligations	4.44M	6.02M	4.39M	53.01M	59.14M	60.74M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	59.92M	97K	49K	0	135K
Total Liabilities	6.84M	92.2M	27.33M	99.66M	121.28M	130.15M
Total Debt+	4.89M	7.43M	6.04M	85.98M	92.43M	97.38M
Net Debt	-36.88M	-27.36M	-155.36M	-34.04M	-40.93M	-81.31M
Debt / Equity	0.11x	-	0.04x	0.86x	0.61x	0.40x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-56.66x	-24.86x	-36.91x
Total Equity+	42.54M	-42.46M	160.78M	99.43M	150.87M	240.97M
Equity Growth %	-	-2%	4.79%	-0.38%	0.52%	0.6%
Book Value per Share	1.71	-1.70	6.72	4.13	2.30	2.15
Total Shareholders' Equity	42.54M	-42.46M	160.78M	99.43M	150.87M	240.97M
Common Stock	0	1K	3K	3K	5K	6K
Retained Earnings	-17.41M	-43.53M	-92.16M	-158.38M	-247.6M	-375.1M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	51K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.52M	-3.02M	-48.68M	-66.5M	-61.36M	-110.82M
Operating CF Margin %	-	-2.79%	-4.8%	-4.91%	-2.92%	-39.35%
Operating CF Growth %	-	0.76%	-15.1%	-0.37%	0.08%	-0.81%
Net Income	-13.66M	-26.13M	-48.63M	-66.22M	-89.22M	-127.5M
Depreciation & Amortization	519K	1.23M	3.33M	5.14M	5.36M	4.11M
Stock-Based Compensation	240K	0	2.52M	4.55M	5.21M	9.55M
Deferred Taxes	0	0	-9.16M	0	0	0
Other Non-Cash Items	78K	517K	9.16M	260K	-315K	-2.03M
Working Capital Changes	299K	21.36M	-5.9M	-10.23M	17.61M	5.05M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	161K	1.13M	10K	528K	-52K	1.99M
Cash from Investing+	-1.25M	-4.24M	-9.94M	-4.22M	-60.76M	-52.61M
Capital Expenditures	-1.25M	-4.24M	-9.94M	-4.22M	-3.15M	-3.83M
CapEx % of Revenue	-	3.91%	0.98%	0.31%	0.15%	1.36%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	34.81M	288K	189.67M	29.36M	135.44M	208.76M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	5K	0	291K	-191K	93.03M	160.32M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-13.77M	-7.26M	-58.62M	-70.73M	-64.5M	-114.65M
FCF Margin %	-	-6.69%	-5.78%	-5.23%	-3.06%	-40.71%
FCF Growth %	-	0.47%	-7.07%	-0.21%	0.09%	-0.78%
FCF per Share	-0.55	-0.29	-2.45	-2.94	-0.98	-1.02
FCF Conversion (FCF/Net Income)	0.92x	0.12x	1.00x	1.00x	0.69x	0.87x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.1%	-64511.11%	-82.2%	-50.9%	-71.29%	-65.08%
Return on Invested Capital (ROIC)	-	-	-	-141.16%	-79.96%	-75.01%
Gross Margin	-	-1796.5%	100%	100%	100%	100%
Net Margin	-	-2408.02%	-479.49%	-489.26%	-423.86%	-4527.66%
Debt / Equity	0.11x	-	0.04x	0.86x	0.61x	0.40x
Interest Coverage	-	-	-	-56.66x	-24.86x	-36.91x
FCF Conversion	0.92x	0.12x	1.00x	1.00x	0.69x	0.87x
Revenue Growth	-	-	834.65%	33.47%	55.52%	-86.62%

Revenue by Segment

	2024
Reportable	2.82M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

TScan Therapeutics, Inc. (TCRX) reported $8.4M in revenue for fiscal year 2024.

TScan Therapeutics, Inc. (TCRX) saw revenue decline by 86.6% over the past year.

TScan Therapeutics, Inc. (TCRX) reported a net loss of $142.6M for fiscal year 2024.

Dividend & Returns

TScan Therapeutics, Inc. (TCRX) has a return on equity (ROE) of -65.1%. Negative ROE indicates the company is unprofitable.

TScan Therapeutics, Inc. (TCRX) had negative free cash flow of $135.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

TScan Therapeutics, Inc. (TCRX) 10-Year Financial Performance & Capital Metrics

TCRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $3M -86.6%
EBITDA -$131M -48.4%
Net Income -$127M -42.9%
EPS (Diluted) -1.14 +16.2%
Gross Margin 100%
EBITDA Margin -4641.8% -1009.1%
Operating Margin -4787.68% -978.3%
Net Margin -4527.66% -968.2%
ROE -65.08% +8.7%
ROIC -75.01% +6.2%
Debt/Equity 0.40 -34.0%
Interest Coverage -36.91 -48.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 17 (bottom 17%)
✗Shares diluted 70.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-34.76%

TTM-10.03%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-28.12%

EPS CAGR

10Y-

5Y-

3Y-

TTM-5.66%

ROCE

10Y Avg-45.72%

5Y Avg-48.81%

3Y Avg-43%

Latest-46.69%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.08M	10.14M	13.54M	21.05M	2.82M
Revenue Growth %	-	-	8.35%	0.33%	0.56%	-0.87%
Cost of Goods Sold+	9.44M	20.58M	0	0	0	0
COGS % of Revenue	-	18.96%	-	-	-	-
Gross Profit+	-9.44M	-19.49M	10.14M	13.54M	21.05M	2.82M
Gross Margin %	-	-17.96%	1%	1%	1%	1%
Gross Profit Growth %	-	-1.06%	1.52%	0.33%	0.56%	-0.87%
Operating Expenses+	4.77M	6.74M	58.78M	80.17M	114.51M	137.64M
OpEx % of Revenue	-	6.21%	5.8%	5.92%	5.44%	48.88%
Selling, General & Admin	4.77M	6.74M	13.83M	20.35M	25.49M	29.56M
SG&A % of Revenue	-	6.21%	1.36%	1.5%	1.21%	10.5%
Research & Development	9.44M	20.58M	44.95M	59.82M	88.15M	107.35M
R&D % of Revenue	-	18.96%	4.43%	4.42%	4.19%	38.12%
Other Operating Expenses	-9.44M	-20.58M	0	0	862K	728K
Operating Income+	-14.21M	-26.23M	-48.64M	-66.64M	-93.46M	-134.82M
Operating Margin %	-	-24.18%	-4.8%	-4.92%	-4.44%	-47.88%
Operating Income Growth %	-	-0.85%	-0.85%	-0.37%	-0.4%	-0.44%
EBITDA+	-13.69M	-25M	-45.31M	-61.5M	-88.1M	-130.71M
EBITDA Margin %	-	-23.04%	-4.47%	-4.54%	-4.19%	-46.42%
EBITDA Growth %	-	-0.83%	-0.81%	-0.36%	-0.43%	-0.48%
D&A (Non-Cash Add-back)	519K	1.23M	3.33M	5.14M	5.36M	4.11M
EBIT	-14.21M	-26.23M	-48.63M	-65.05M	-85.46M	-123.85M
Net Interest Income+	552K	106K	16K	415K	4.24M	8.41M
Interest Income	552K	106K	16K	1.59M	8M	12.06M
Interest Expense	0	0	0	1.18M	3.76M	3.65M
Other Income/Expense	552K	106K	16K	415K	4.24M	7.32M
Pretax Income+	-13.66M	-26.13M	-48.63M	-66.22M	-89.22M	-127.5M
Pretax Margin %	-	-24.08%	-4.79%	-4.89%	-4.24%	-45.28%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-13.66M	-26.13M	-48.63M	-66.22M	-89.22M	-127.5M
Net Margin %	-	-24.08%	-4.79%	-4.89%	-4.24%	-45.28%
Net Income Growth %	-	-0.91%	-0.86%	-0.36%	-0.35%	-0.43%
Net Income (Continuing)	-13.66M	-26.13M	-48.63M	-66.22M	-89.22M	-127.5M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.53	-1.04	-2.03	-2.74	-1.36	-1.14
EPS Growth %	-	-0.96%	-0.95%	-0.35%	0.5%	0.16%
EPS (Basic)	-0.53	-1.04	-2.03	-2.74	-1.36	-1.14
Diluted Shares Outstanding	24.94M	24.94M	23.91M	24.05M	65.6M	111.99M
Basic Shares Outstanding	24.94M	24.94M	23.91M	24.05M	65.6M	111.99M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	42.38M	36.45M	165.65M	124.13M	194.24M	292.72M
Cash & Short-Term Investments	41.76M	34.79M	161.41M	120.03M	192.04M	290.11M
Cash Only	41.76M	34.79M	161.41M	120.03M	133.36M	178.69M
Short-Term Investments	0	0	0	0	58.69M	111.42M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	4.25M	4.1M	2.19M	2.61M
Total Non-Current Assets+	7M	13.29M	22.45M	74.96M	77.91M	78.4M
Property, Plant & Equipment	6.41M	12.53M	17.26M	69.2M	71.23M	71.6M
Fixed Asset Turnover	-	0.09x	0.59x	0.20x	0.30x	0.04x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	5.2M	5.04M	0	0
Other Non-Current Assets	595K	761K	0	725K	6.68M	6.8M
Total Assets+	49.38M	49.74M	188.11M	199.09M	272.15M	371.12M
Asset Turnover	-	0.02x	0.05x	0.07x	0.08x	0.01x
Asset Growth %	-	0.01%	2.78%	0.06%	0.37%	0.36%
Total Current Liabilities+	2.4M	17.45M	21.34M	17.3M	29.82M	35.96M
Accounts Payable	1.01M	2.91M	1.76M	2.91M	2.37M	4.28M
Days Payables Outstanding	39.04	51.62	-	-	-	-
Short-Term Debt	0	0	1.65M	3.68M	3.35M	0
Deferred Revenue (Current)	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	31K	1.67M	3.92M	2.48M	5.9M	6.92M
Current Ratio	17.69x	2.09x	7.76x	7.17x	6.51x	8.14x
Quick Ratio	17.69x	2.09x	7.76x	7.17x	6.51x	8.14x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	4.44M	74.75M	5.99M	82.35M	91.46M	94.19M
Long-Term Debt	0	0	0	29.29M	26.7M	32.07M
Capital Lease Obligations	4.44M	6.02M	4.39M	53.01M	59.14M	60.74M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	59.92M	97K	49K	0	135K
Total Liabilities	6.84M	92.2M	27.33M	99.66M	121.28M	130.15M
Total Debt+	4.89M	7.43M	6.04M	85.98M	92.43M	97.38M
Net Debt	-36.88M	-27.36M	-155.36M	-34.04M	-40.93M	-81.31M
Debt / Equity	0.11x	-	0.04x	0.86x	0.61x	0.40x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-56.66x	-24.86x	-36.91x
Total Equity+	42.54M	-42.46M	160.78M	99.43M	150.87M	240.97M
Equity Growth %	-	-2%	4.79%	-0.38%	0.52%	0.6%
Book Value per Share	1.71	-1.70	6.72	4.13	2.30	2.15
Total Shareholders' Equity	42.54M	-42.46M	160.78M	99.43M	150.87M	240.97M
Common Stock	0	1K	3K	3K	5K	6K
Retained Earnings	-17.41M	-43.53M	-92.16M	-158.38M	-247.6M	-375.1M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	51K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.52M	-3.02M	-48.68M	-66.5M	-61.36M	-110.82M
Operating CF Margin %	-	-2.79%	-4.8%	-4.91%	-2.92%	-39.35%
Operating CF Growth %	-	0.76%	-15.1%	-0.37%	0.08%	-0.81%
Net Income	-13.66M	-26.13M	-48.63M	-66.22M	-89.22M	-127.5M
Depreciation & Amortization	519K	1.23M	3.33M	5.14M	5.36M	4.11M
Stock-Based Compensation	240K	0	2.52M	4.55M	5.21M	9.55M
Deferred Taxes	0	0	-9.16M	0	0	0
Other Non-Cash Items	78K	517K	9.16M	260K	-315K	-2.03M
Working Capital Changes	299K	21.36M	-5.9M	-10.23M	17.61M	5.05M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	161K	1.13M	10K	528K	-52K	1.99M
Cash from Investing+	-1.25M	-4.24M	-9.94M	-4.22M	-60.76M	-52.61M
Capital Expenditures	-1.25M	-4.24M	-9.94M	-4.22M	-3.15M	-3.83M
CapEx % of Revenue	-	3.91%	0.98%	0.31%	0.15%	1.36%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	34.81M	288K	189.67M	29.36M	135.44M	208.76M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	5K	0	291K	-191K	93.03M	160.32M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-13.77M	-7.26M	-58.62M	-70.73M	-64.5M	-114.65M
FCF Margin %	-	-6.69%	-5.78%	-5.23%	-3.06%	-40.71%
FCF Growth %	-	0.47%	-7.07%	-0.21%	0.09%	-0.78%
FCF per Share	-0.55	-0.29	-2.45	-2.94	-0.98	-1.02
FCF Conversion (FCF/Net Income)	0.92x	0.12x	1.00x	1.00x	0.69x	0.87x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.1%	-64511.11%	-82.2%	-50.9%	-71.29%	-65.08%
Return on Invested Capital (ROIC)	-	-	-	-141.16%	-79.96%	-75.01%
Gross Margin	-	-1796.5%	100%	100%	100%	100%
Net Margin	-	-2408.02%	-479.49%	-489.26%	-423.86%	-4527.66%
Debt / Equity	0.11x	-	0.04x	0.86x	0.61x	0.40x
Interest Coverage	-	-	-	-56.66x	-24.86x	-36.91x
FCF Conversion	0.92x	0.12x	1.00x	1.00x	0.69x	0.87x
Revenue Growth	-	-	834.65%	33.47%	55.52%	-86.62%

Revenue by Segment

	2024
Reportable	2.82M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

TScan Therapeutics, Inc. (TCRX) reported $8.4M in revenue for fiscal year 2024.

TScan Therapeutics, Inc. (TCRX) saw revenue decline by 86.6% over the past year.

TScan Therapeutics, Inc. (TCRX) reported a net loss of $142.6M for fiscal year 2024.

Dividend & Returns

TScan Therapeutics, Inc. (TCRX) has a return on equity (ROE) of -65.1%. Negative ROE indicates the company is unprofitable.

TScan Therapeutics, Inc. (TCRX) had negative free cash flow of $135.9M in fiscal year 2024, likely due to heavy capital investments.